• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

The SPICE III trial: dexmedetomidine is rarely effective as a sole agent for sedation of ICU patients

byDayton McMillan
May 31, 2019
in Cardiology, Neurology, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients in the intensive care unit (ICU) randomized to continue sedation for ventilation with dexmedetomidine often required use of supplementary propofol, midazolam, or both to achieve the prescribed level of sedation.

2. The rate of death from any cause at 90 days after randomization was similar between patients assigned to the dexmedetomidine group or those undergoing traditional sedation with propofol, midazolam, or other sedatives.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Sedation of critically ill patients on ventilation is a part of their medical care, though the best choice of sedative is not definitively known. Dexmedetomidine, an adrenergic agonist of the alpha-2 receptor, may provide benefit as a sedative compared to traditional propofol or midazolam agents. Prior studies have shown an association between dexmedetomidine use and shorter times to extubation, reduced delirium, and lower mortality compared to other sedatives. The SPICE III trial (Sedation Practice in Intensive Care Evaluation) evaluated dexmedetomidine versus traditional sedative agents and found patients randomized to either group had similar rates of all-cause mortality at 90 days. Most patients in the dexmedetomidine group also required use of additional sedative agents to maintain a desired state of sedation.

This large randomized trial provides evidence that mortality among patients sedated with dexmedetomidine compared to traditional agents is generally equivocal, and that dexmedetomidine is often not an agent that can be used alone. The study’s strengths include the randomized design, large number of patients recruited, and thorough subgroup analysis. Limitations include lack of assessment of other ICU associated treatment in the groups, such as vasopressor use, fluid administration, etc.

Click to read the study in NEJM

Relevant Reading: Effect of dexmedetomidine added to standard care on ventilator-free time in patients with agitated delirium: a randomized clinical trial

RELATED REPORTS

Sublingual dexmedetomidine reduces agitation in patients with acute agitation associated with bipolar disorder

Dexmedetomidine and propofol had similar outcomes in septic, mechanically ventilated adults

#VisualAbstract: Early Sedation with Dexmedetomidine in Critically Ill Patients

In-Depth [randomized controlled trial]: This international, open-label, randomized controlled trial enrolled patients between 2013 and 2018. Eligible patients were receiving endotracheal tube ventilation, were expected to continue this treatment for one or more days, and were receiving sedatives. Exclusion criteria included age less than 18 years old, intubation in the ICU more than 12 hours prior to enrollment, and suspected or proven primary brain injury. The sedation target for patients as defined by the Richmond Agitation and Sedation Scale (RASS) was between -2 and 1 (lightly sedated to restless). Patients were randomized to a dexmedetomidine (n=1954) or usual-care (n=1964) group, which included use of propofol, midazolam, or other agents as prescribed by the treating clinician. In a modified intention-to-treat analysis, the primary outcome of rate of all-cause death at 90 days after enrollment was 29.1% in both treatment groups (adjusted risk difference, 0.0 percentage points; 95% confidence interval [CI], −2.9 to 2.8; P=0.98). For patients with proven or suspected sepsis, there was also no difference between groups in 90-day mortality rates. To achieve the desired level of sedation in the first two days, over 70% of patients in the dexmedetomidine group required use of additional sedatives. Approximately 80% of patients in both groups also received fentanyl. Adverse and severe adverse events were more commonly reported in the dexmedetomidine group (0.7% vs 0.1%, P=0.003). The most common adverse events were bradycardia and hypotension.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: dexmedetomidinefentanylmidazolamprecedexpropofolsedation
Previous Post

Quick Take: Genomic characterization of metastatic breast cancers

Next Post

#VisualAbstract: Diabetes-Related Emotional Distress Over Time

RelatedReports

Children’s hospital visits for suicide ideation and attempts are increasing
Emergency

Sublingual dexmedetomidine reduces agitation in patients with acute agitation associated with bipolar disorder

February 25, 2022
Noninvasive ventilation beneficial in abdominal surgery patients with hypoxemic respiratory failure
Infectious Disease

Dexmedetomidine and propofol had similar outcomes in septic, mechanically ventilated adults

April 28, 2021
#VisualAbstract: Early Sedation with Dexmedetomidine in Critically Ill Patients
StudyGraphics

#VisualAbstract: Early Sedation with Dexmedetomidine in Critically Ill Patients

August 22, 2020
Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use
Chronic Disease

Risk Evaluation and Mitigation Strategy (REMS) program shows high rates of inappropriate transmucosal immediate-release fentanyl prescribing

February 27, 2019
Next Post
#VisualAbstract: Diabetes-Related Emotional Distress Over Time

#VisualAbstract: Diabetes-Related Emotional Distress Over Time

Increased number of daily steps linked with decreased mortality in older women

Increased number of daily steps linked with decreased mortality in older women

Cerebral protection device effective in patients undergoing transcatheter aortic valve implantation

Ambulatory rhythm monitoring detects heart block after transcatheter aortic valve replacement

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.